Rbl 2h3

Rat basophilic leukemia (RBL)-2H3 and the human mast cell line (HMC-1) were purchased from ATCC (Manassas, VA, USA) and Sigma-Aldrich. The RBL-2H3 and HMC-1 cell line were cultured in Dulbecco’s Modified Eagle’s medium (DMEM, GIBCO, Grand Island, NY, USA) and Iscove’s Modified Dulbecco’s Medium (IMDM, GIBCO), respectively, and then supplemented with heat-inactivated 10% fetal bovine serum (FBS, GIBCO) and 1% antibiotic–antimycotic (comprising 10,000 units/mL penicillin, 25 μg/mL amphotericin B, and 10,000 μg/mL streptomycin, GIBCO). Cells were incubated at 37 °C in 5% CO₂. The cells of passages 5–8 were used in this study.

Dexamethasone (Dexa), anti-dinitrophenyl (DNP) IgE, DNP-human serum albumin (HSA), ovalbumin (OVA), and Histodenz were purchased from Sigma-Aldrich (St. Louis, MO), and alum adjuvant was purchased from Thermo Fisher Scientific (Waltham, MA). Rat basophilic leukemia (RBL-2H3) cells purchased from Korean Cell Line Bank (Seoul, Republic of Korea). RBL-2H3, rat peritoneal mast cells (RPMC), and mouse bone marrow-derived mast cells (mBMMC) were grown at 37°C in 5% CO₂ in Dulbecco's modified Eagle's medium, α-minimum essential medium (Gibco, Grand Island, NY) and RPMI 1640 (Hyclone, Logan, UT), respectively, supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin G, 100 μg/mL streptomycin, and 250 ng/mL amphotericin B. In addition, complete RPMI 1640 media was supplemented by 4 mM L-glutamine, 25 M HEPES, 50 μM 2-mercaptoethanol, 1 mM sodium pyruvate, MEM non-essential amino acid solution (Gibco), 10 ng/mL murine IL-3, and 2 ng/mL murine SCF (PeproTech, Rocky Hill, NJ). RBL-2H3 were used throughout the study at passages ranging from 4 to 8.